Fibrinogen plays an essential role in haemostasis. In the presence of thrombin, activated coagulation factor XIII and calcium ions, fibrinogen is converted into a fibrin clot. Riastap is a concentrated fibrinogen replacement product prepared from human plasma.1
In a pivotal phase II pharmacokinetic study, 14 patients with afibrinogenaemia received a single 70mg/kg iv infusion of human fibrinogen concentrate. After one hour, maximum clot firmness had increased by a mean of 8.9mm from baseline (p<0.0001). Four mild adverse reactions were reported, none of which were serious or related to study drug.2
- Riastap Summary of Product Characteristics, March 2011.
- Manco-Johnson MJ et al. J Thromb Haemost 2009; 7: 2064–9.
Further information: CSL